IBBBiS: Inflammation and Blood Brain Barrier Integrity as Biomarkers of Suicidal Behavior
Study Details
Study Description
Brief Summary
Recent studies have revealed an association between history of suicide attempt and inflammatory markers in both the cerebrospinal fluid and the plasma. Post mortem studies have shown an increase in microglial activation in the brain tissue of suicide victims. However the relationship between peripheral and central inflammation in suicide is probably mediated by complex biological processes that are yet elucidated. An increase of blood S100B levels (biomarker of neurovascular damage; PMID 14530574) has been reported in adolescents with suicidal ideation vs. controls and independently of psychiatric disorder.
The investigators hypothesize that peripheral inflammation may alter the blood brain barrier, which normally acts as a filter to ensure proper neuronal functioning, in suicidal patients.
They propose to investigate peripheral inflammation, neurovascular permeability and miRNAs in suicidal behavior pathophysiology as biomarkers of suicidal behavior in depression
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
150 participants will be enrolled, divided into 3 groups:
-
50 Suicide attempters, i.e. currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempts, including the most recent);
-
50 Affective controls, i.e. currently depressed patients without any lifetime history of suicide attempt;
-
50 Healthy controls (age- and gender-matched to patients' groups) with no lifetime history of psychiatric disorders.
The protocol includes two visits for patients (suicide attempters and affective controls) and only one visit (inclusion) for healthy controls.
The first visit is the inclusion visit (Day 0-Day 8). Day 0 is the date of the last suicide attempt for the suicide attempters group and the date of signature of the consent for the affective control and healthy control groups. All the visit exams will be performed within 8 days after Day 0.
The second visit takes place one month +/- one week after inclusion. At each visit, a clinical assessment will be performed to characterise psychopathology and suicidal characteristics. Blood samples will be obtained in order to measure inflammatory markers. An MRI will be performed on order to study white matter microstructure and brain functional connectivity networks.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Suicide attempters Currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempt including the most recent ); |
Biological: Blood samples
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Other: Hetero-questionnaires and auto-questionnaires
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Other: Magnetic Resonance Imaging (MRI)
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
|
| Active Comparator: Affective controls Currently depressed patients without any lifetime history of suicide attempt |
Biological: Blood samples
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Other: Hetero-questionnaires and auto-questionnaires
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Other: Magnetic Resonance Imaging (MRI)
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
|
| Active Comparator: Healthy controls Participants with no lifetime history of psychiatric disorders |
Biological: Blood samples
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Other: Hetero-questionnaires and auto-questionnaires
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Other: Magnetic Resonance Imaging (MRI)
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
|
Outcome Measures
Primary Outcome Measures
- Level of blood S100B assayed in the 3 groups, a marker of cerebral and vascular lesions. [At inclusion]
- Level of blood S100B assayed in the 3 groups, a marker of cerebral and vascular lesions. [At 1 month follow-up]
Secondary Outcome Measures
- Cytokines' concentration by multiplex ELISA (pg/ml) [At inclusion]
C-C motif chemokine ligand (CCL)2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL20, CCL22, CCL26, C-X-C motif chemokine ligand (CXCL)10, Interleukin (IL)-1α, IL 1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23 p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL- 27, IL-31, interferon (IFN)-γ, Tumor Necrosis Factor ðTNFÞ α, TNF ß and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Cytokines' concentration by multiplex ELISA (pg/ml) [At 1 month follow-up]
C-C motif chemokine ligand (CCL)2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL20, CCL22, CCL26, C-X-C motif chemokine ligand (CXCL)10, Interleukin (IL)-1α, IL 1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23 p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL- 27, IL-31, interferon (IFN)-γ, Tumor Necrosis Factor ðTNFÞ α, TNF ß and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Specific proteins measurement (pg/ml) [At inclusion]
Specific proteins measurement (i.e. GFAP, NFL, UHC-L1, sGPR56, S100B, MBP and related proteins) using digital or classical ELISA or western blot
- Specific proteins measurement (pg/ml) [At 1 month follow-up]
Specific proteins measurement (i.e. GFAP, NFL, UHC-L1, sGPR56, S100B, MBP and related proteins) using digital or classical ELISA or western blot
- FACS analysis on fresh blood [At inclusion]
Determination of the number of white cells
- FACS analysis on fresh blood [At 1 month follow-up]
Determination of the number of white cells
- FACS analysis on fresh blood [At inclusion]
Description of the phenotype of white cells
- FACS analysis on fresh blood [At 1 month follow-up]
Description of the phenotype of white cells
- FACS analysis on fresh blood [At inclusion]
Percentage of cellular inflammatory marker
- FACS analysis on fresh blood [At 1 month follow-up]
Percentage of cellular inflammatory marker
- Extraction of small and long RNA [At inclusion]
Use of RNA-seq, RT-qPCR and digital PCR to quantify RNA
- Extraction of small and long RNA [At 1 month follow-up]
Use of RNA-seq, RT-qPCR and digital PCR to quantify RNA
- Test of the capacity of leukocytes isolated from patients to provoke vascular inflammation and BBB permeabilization [At inclusion]
These experiments will be performed using an in vitro model of vascular cell co-culture. The reactivity of leukocytes to pro-inflammatory challenges and cytokines will be tested.
- Test of the capacity of leukocytes isolated from patients to provoke vascular inflammation and BBB permeabilization [At 1 month follow-up]
These experiments will be performed using an in vitro model of vascular cell co-culture. The reactivity of leukocytes to pro-inflammatory challenges and cytokines will be tested.
- White matter microstructure analysis [At inclusion]
The ihMT (ihMTR) and MT (MTR) ratios will be performed in the apparently normal white and gray matter regions from regional white matter and gray matter atlases
- White matter microstructure analysis [At 1 month follow-up]
The ihMT (ihMTR) and MT (MTR) ratios will be performed in the apparently normal white and gray matter regions from regional white matter and gray matter atlases
- White matter microstructure analysis [At inclusion]
Value of the fraction of anisotropy (FA) along the skeleton of the Tract-based spatial statistics TBSS
- White matter microstructure analysis [At 1 month follow-up]
Value of the fraction of anisotropy (FA) along the skeleton of the Tract-based spatial statistics TBSS
- White matter microstructure analysis [At inclusion]
Extraction by anatomical region of FA, mean, axial and radial diffusivity [FSL software)
- White matter microstructure analysis [At 1 month follow-up]
Extraction by anatomical region of FA, mean, axial and radial diffusivity [FSL software)
- White matter microstructure analysis [At inclusion]
Value of diffusion of blood water D* (pseudocoefficient =perfusive composante) from different region based on regional atlases
- White matter microstructure analysis [At 1 month follow-up]
Value of diffusion of blood water D* (pseudocoefficient =perfusive composante) from different region based on regional atlases
- White matter microstructure analysis [At inclusion]
Value of diffusion of the tissue (ADC) from different region based on regional atlases
- White matter microstructure analysis [At 1 month follow-up]
Value of diffusion of the tissue (ADC) from different region based on regional atlases
- White matter microstructure analysis [At inclusion]
Value of fraction of perfusion fD* ( incoherent blood signal divided by total incoherent signal) from different region based on regional atlases
- White matter microstructure analysis [At 1 month follow-up]
Value of fraction of perfusion fD* ( incoherent blood signal divided by total incoherent signal) from different region based on regional atlases
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At inclusion]
Regional homogeneity
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At 1 month follow-up]
Regional homogeneity
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At inclusion]
Amplitude of low frequency fluctuations
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At 1 month follow-up]
Amplitude of low frequency fluctuations
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At inclusion]
Functional homotopy
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At 1 month follow-up]
Functional homotopy
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At inclusion]
Graph theory metrics
- Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel [At 1 month follow-up]
Graph theory metrics
- Cerebral morphometric extraction (3DT1): automatic segmentation [At inclusion]
Evaluation of the volume from cerebral anatomical atlas
- Cerebral morphometric extraction (3DT1): automatic segmentation [At 1 month follow-up]
Evaluation of the volume from cerebral anatomical atlas
- Cerebral morphometric extraction (3DT1): automatic segmentation [At inclusion]
Evaluation of the surface from cerebral anatomical atlas
- Cerebral morphometric extraction (3DT1): automatic segmentation [At 1 month follow-up]
Evaluation of the surface from cerebral anatomical atlas
- Cerebral morphometric extraction (3DT1): automatic segmentation [At inclusion]
Evaluation of the cortical thickness from cerebral anatomical atlas
- Cerebral morphometric extraction (3DT1): automatic segmentation [At 1 month follow-up]
Evaluation of the cortical thickness from cerebral anatomical atlas
- Cerebral blood analysis [At inclusion]
Extraction of blood flow values from 3D PCASL acquisition from vascular atlas
- Cerebral blood analysis [At 1 month follow-up]
Extraction of blood flow values from 3D PCASL acquisition from vascular atlas
Eligibility Criteria
Criteria
Common inclusion criteria:
-
Aged between 18 and 55 years old,
-
Affiliated to a French National Social Security System
-
Able to understand the nature, purpose and methodology of the study
-
Able to give written informed consent
Specific inclusion criteria
Suicide attempters:
-
Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion)
-
Subject with a recent history of proven suicide attempt (within the 8 days before inclusion)
-
Subject with a history of maximum 2 previous lifetime proven SA
Affective controls:
-
Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion),
-
Subject without any lifetime history suicidal behavior (proven, interrupted or aborted)
Healthy controls:
- Subject who have no current or past personal history of psychiatric disorders according to DSM5 criteria.
Non inclusion criteria
-
History of psychotic disorders
-
Diagnostic of illicit substance / alcohol use disorder within the last 6 months
-
Current inflammation-related symptoms including fever and infectious or inflammatory disease
-
Severe symptomatic or unstable medical condition (e.g., unstable endocrine or cardiovascular disease)
-
Medical disorders affecting CNS function (e.g., history of severe head trauma, epilepsy, tumor)
-
Current use of specific medications known to affect the immune system, such as corticosteroids, non-steroid anti-inflammatory drugs, aspirin and statins
-
Contraindication to MRI or impossibility to assess, or doubt about a contraindication to the MRI: metallic artificial heart valve, pacemaker, cerebrovascular clips ferromagnetic materials, metallic foreign body that can be mobilized, in particular cerebral or intraocular, prosthesis ferromagnetic, impossibility of absolute immobility in supine position, claustrophobia.
-
Vaccination in the last month
-
Law protected or deprived of liberty subject
-
Pregnant and breastfeeding women
-
BMI > 30 kg/m2
-
Having reached 6000€ annual compensation for participating to clinical trials
-
Being in exclusion period for another study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University hospital | Montpellier | France | 34295 |
Sponsors and Collaborators
- University Hospital, Montpellier
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RECHMPL22_0103